Cyber Incident Victim: Octapharma
Date:
Apr 2024
Location:
United States of America
Summary
Octapharma Plasma USA detected suspicious network activity, prompting immediate activation of incident response protocols and system shutdowns to contain potential impacts. Operations at U.S. plasma donation centers were temporarily suspended while recovery efforts commenced, with updates promised through official channels; European facilities including German donation centers and production sites remained unaffected and continued normal operations throughout the incident.
| CIA Posture | Motives | Tactics, Techniques & Procedures |
|---|---|---|
| Available to members | 1 motive | 1 technique |
| Threat Actors | Type | Location |
|---|---|---|
| 0 actors | Available to members | Available to members |
Description
On Wednesday, April 17, 2024, Octapharma Plasma USA identified suspicious activity occurring within its network infrastructure. The organization promptly activated its predefined incident response protocols to investigate the nature and extent of the anomalous activity. As a precautionary containment measure, Octapharma took affected systems offline to prevent potential lateral movement or escalation of the incident across its network environment. This operational disruption impacted plasma donation centers across the United States, necessitating their temporary closure while systems remained inaccessible. The company prioritized containment and forensic analysis during the initial response phase, though specific technical details regarding the attack vector, intrusion methods, or data compromise were not publicly disclosed in available communications.
Octapharma Plasma confirmed its European operations remained unaffected by the incident, with plasma donation centers in Germany continuing normal operations throughout the event. The company's European production facilities similarly maintained uninterrupted operations, allowing plasma processing and manufacturing activities to proceed according to established schedules. Recovery efforts focused exclusively on restoring functionality to U.S.-based donation centers, with staff working to reinstate systems and resume donor services. Octapharma directed stakeholders to monitor its official website for operational updates regarding center reopenings, though no specific timeline for full restoration was provided in the initial announcement. The incident's impact appeared geographically contained to U.S. operations, with no observed spillover effects on international facilities or production capabilities as of the last published update.